News | January 30, 2007

Companies Collaborate to Combat Deadly Plaque

Jan. 31, 2007 — BG Medicine (BGM) has announced its participation in an alliance with Merck & Co., AstraZeneca, Royal Philips Electronics and Humana in which the companies have formed the High-Risk Plaque (HRP) Initiative. The key objective of the HRP will be to research and advance the understanding, recognition and management of high-risk plaque, the primary underlying cause of heart attacks.

By collaborating on the discovery and development of improved techniques for identifying individuals at risk for heart attacks, as well as the advancement for monitoring disease progressions and response to treatment, the initiative takes direct aim against morbidity, mortality and cost associated with cardiovascular disease.

The companies indicate that their HRP Initiative will leverage recent advances in biology and technology to design and optimize a care-cycle for high-risk plaque.

Plaque research over the last five years has told doctors that cholesterol deposits (plaque) in the coronary and carotid arteries show inflammation, and inflamed plaque — known as vulnerable plaques — can rupture without prior symptoms. When vulnerable plaque erupts in coronary arteries, blood flow is obstructed, delivering a deathblow to hundreds of thousands of unsuspecting, asymptomatic victims every year.

"The HRP Initiative is expected to make important contributions to the development of a cost-effective care-cycle for this common condition that is responsible for much suffering, disability and death in the world,” said Valentin Fuster, M.D., Ph.D., chairman of the Scientific Advisory Board for the HRP Initiative. “The HRP Initiative covers a broad spectrum of pertinent issues, from molecular markers to the role of lifestyle interventions."

Dr. Fuster is a leading international cardiologist who serves as director of the Zena and Michael A. Weiner Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health and director of Mount Sinai Heart.

Erling Falk, M.D., Ph.D., a prominent cardiovascular pathologist who co-chairs the Scientific Advisory Board for the HRP Initiative added, "Coming together under the umbrella of the HRP Initiative to work collaboratively to move research and development of this important disease forward will improve diagnosis and treatment of patients at high risk for serious cardiovascular disease."

Dr. Falk is professor of Cardiovascular Pathology, Department of Cardiology, University of Aarhus, Aarhus, Denmark.

Companies involved in the HRP Initiative estimate they will provide $30 million in funding over four years — the group will ultimately be comprised of six sponsoring companies BG Medicine, a biotechnology research company based in Waltham, MA, is serving as the project coordinator.

For more information visit www.bg-medicine.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init